Anavex Life Sciences Corp (AVXL)

[sokol]

Yes, but while we are at it - placing emphasis on “may qualify” - : “After September 30, 2022, FDA MAY NOT (emphasis added) award any rare pediatric disease priority review vouchers.” Therefore, the FDA may or may not award a voucher after September 30, 2022, and Anavex may or may not qualify. Additionally, Anavex may or may not otherwise meet the September 30, 2022, deadline. I think too that the exceptions may be made for drug trials that may have been delayed by the C-virus.